Cargando…
Schistosome Sulfotransferases: Mode of Action, Expression and Localization
Oxamniquine (OXA) is a prodrug activated by a sulfotransferase (SULT) that was only active against Schistosoma mansoni. We have reengineered OXA to be effective against S. haematobium and S. japonicum. Three derivatives stand out, CIDD-0066790, CIDD-0072229, and CIDD-0149830 as they kill all three m...
Autores principales: | Guzman, Meghan A., Rugel, Anastasia, Alwan, Sevan N., Tarpley, Reid, Taylor, Alexander B., Chevalier, Frédéric D., Wendt, George R., Collins, James J., Anderson, Timothy J. C., McHardy, Stanton F., LoVerde, Philip T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323829/ https://www.ncbi.nlm.nih.gov/pubmed/35890311 http://dx.doi.org/10.3390/pharmaceutics14071416 |
Ejemplares similares
-
An iterative process produces oxamniquine derivatives that kill the major species of schistosomes infecting humans
por: Guzman, Meghan A., et al.
Publicado: (2020) -
Addressing the oxamniquine in vitro-in vivo paradox to facilitate a new generation of anti-schistosome treatments
por: Toth, Katalin, et al.
Publicado: (2023) -
Why does oxamniquine kill Schistosoma mansoni and not S. haematobium and S. japonicum?
por: Rugel, Anastasia R., et al.
Publicado: (2020) -
Rational approach to drug discovery for human schistosomiasis
por: LoVerde, Philip T., et al.
Publicado: (2021) -
Corrigendum to “Rational approach to drug discovery for human schistosomiasis” [Int. J. Parasitol. Drugs Drug Resist. 16 (2021) 140–147]
por: LoVerde, Philip T., et al.
Publicado: (2022)